Tenderwize
Wróć do wyszukiwania

Open House Originale rebate agreement for Lamivudine/Abacavir/Dolutegravir

Techniker Krankenkasse·Hamburg, Germany·Deadline Feb 27, 2027 · 186 days left·Open·Supplies
Zarejestruj się, aby zapisaćOpen documents
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-07 - Lamivudin/Abacavir/Dolutegravir (Wirkstoffkombination)

46/100

Ocena szansy

Needs reviewMedium complexity
SuppliesOpen
Skąd ta ocena?

Szansa

46 / 100

Złożoność

58 / 100

Czynniki ryzyka

Submission through the portal is not allowed; the notice requires email with qualified electronic signature or postal s...

Only pharmaceutical companies meeting the AMG and authorisation conditions may participate; local representatives are e...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Supplies contract
  • 1 lot
  • Duration until Feb 2027
  • Supply of pharmaceutical products for the medicinal combination Lamivudin/Abacavir/Dolutegravir.
  • Open House rebate agreements under § 130c(1) SGB V.
Pokaż pełne podsumowanie

This is an Open House supply arrangement by Techniker Krankenkasse for the pharmaceutical product combination Lamivudin/Abacavir/Dolutegravir (CPV 33600000). The notice states that all suitable pharmaceutical companies may join during the contract period, with no individual negotiations and no exclusivity. The contract runs from 01.03.2025 to 28.02.2027 at the latest, but no contract value is provided. Participation and contract documents are only available electronically via the buyer portal, while submission is not allowed through the portal and must be made by email with qualified electronic signature or by post. The notice also states that the publication is not considered a public procurement contract under procurement law, so remedies are directed to social courts rather than procurement review bodies.

Ryzyka

Submission through the portal is not allowed; the notice requires email with qualified electronic signature or postal s...

Only pharmaceutical companies meeting the AMG and authorisation conditions may participate; local representatives are e...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Applicant must be a pharmaceutical company within the meaning of § 4(18) AMG for the offered medicinal products.
  • Applicant must have its seat in Germany, another EU Member State, or another EEA State.
  • Applicant must hold a valid marketing authorisation for the relevant medicinal product(s), or otherwise be entitled to place them on the market in its own name.

Zamawiający

Lokalizacja

Hamburg, DEU

Identyfikator

992-80116-93

Działalność

Health

Części (1)

LOT-0001

Open House Originale rebate agreement for Lamivudine/Abacavir/Dolutegravir

Single lot covering Open House rebate agreements for the medicinal product combination Lamivudin/Abacavir/Dolutegravir. The scope is nationwide in Germany and the arrangement is open to all suitable pharmaceutical companies meeting the stated eligibility conditions. Source: structured data and XML notice.

SuppliesEU fundedElectronic submission

Lokalizacja

DE600, Germany

Czas trwania

Feb 2025 - Feb 2027

Kategoria

Pharmaceutical products

Termin

Deadline Feb 27, 2027

Szczegóły zamówienia

Data publikacji
20 Jan 2025
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
42947-2025

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3